Beijing in talks for license rights on Pfizer's Paxlovid

The People's Republic of China is negotiating license rights for Pfizer's antiviral drug Paxlovid.

If successful, that would allow domestic Chinese pharmaceutical companies to manufacture and distribute a generic version of the drug, Reuters reported citing three sources.

Beijing's aim was to have a deal in place before the Lunar New Year on 22 January, one source reportedly said.

-- More to follow --